<DOC>
	<DOCNO>NCT02455843</DOCNO>
	<brief_summary>This study multicenter , randomize , open-label Phase III trial compare microwave plus chemotherapy versus chemotherapy patient advance non-small cell lung cancer . The primary endpoint progression free survival ( PFS ) key secondary endpoint overall survival ( OS ) . A total 400 eligible patient randomize receive either microwave ablation combinated first-line platinum-based doublet chemotherapy first-line platinum-based doublet chemotherapy 1:1 ratio patient . The response microwave ablation assess expert consensus thermal ablation primary metastatic lung tumor . Tumor response progression assess accord Response Evaluation Criteria Solid Tumors（RECIST）1.1 .</brief_summary>
	<brief_title>Microwave Plus Chemotherapy Versus Chemotherapy Advanced NSCLC</brief_title>
	<detailed_description>Patients randomize treated microwave ablation chemotherapy treat chemotherapy alone .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Diagnosis advance stage NSCLC ( stage IIIB IV ) confirm histology cytology method . 2 . Measurable disease primary tumor site accord RECIST1.1 . 3 . Eastern Cooperative Oncology Group ( ECOG ) score 02 4 . Adequate organ function , define follow : 1 . Left ventricular ejection fraction &gt; 50 % within institution normal value . 2 . Absolute neutrophil count ( ANC ) &gt; 1500/mm3 . 3 . Platelet count &gt; 75,000/mm3 4 . Estimated creatinine clearance &gt; 45m1/min . 5 . Total bilirubin &lt; 1.5 time institutional ULN ( Patients Gilbert 's Syndrome total bilirubin must &lt; 4 time institutional ULN ) . 6 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &lt; three time institutional upper limit normal ( ULN ) ( relate liver metastasis &lt; five time institutional ULN ) . 5 . Age ≥ 18 year . 6 . Written inform consent consistent International Conference Harmonization ( ICH ) Good Clinical Practice（GCP） guideline . 1 . Previous anticancer treatment include chemotherapy , radiation therapy target therapy.. 2 . Active symptomatic brain metastasis . Dexamethasone therapy allow administer stable dose least 4 week randomization . 3 . Any current malignancy malignancy diagnose within past five ( 5 ) year . 4 . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New York Heart Association （NYHA） classification 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior randomisation . 5 . Any concomitant serious illness organ system dysfunction opinion investigator would either compromise patient safety interfere evaluation safety test drug . 6 . Women childbearing potential men able father child , unwilling abstinent use adequate contraception prior study entry . 7 . Female patient childbearing potential nursing pregnant . 8 . Patients unable comply protocol opinion investigator . 9 . Active hepatitis B infection ( define presence Hepatitis B DNA ) , active hepatitis C infection ( define presence Hepatitis C RNA ) and/or know HIV carrier . 10 . Known suspected active drug alcohol abuse opinion investigator . 11 . Major surgery within 4 week start study treatment . Use investigational drug within 4 week randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>microwave ablation</keyword>
	<keyword>chemotherapy</keyword>
</DOC>